ID: ALA3706925

Max Phase: Preclinical

Molecular Formula: C27H28N4O2

Molecular Weight: 440.55

Molecule Type: Small molecule

Representations

Canonical SMILES:  C[C@H]1CN(c2cccc3cc(C#N)ccc23)CCN1CC[C@H]1OCc2cc(C(N)=O)ccc21

Standard InChI:  InChI=1S/C27H28N4O2/c1-18-16-31(25-4-2-3-20-13-19(15-28)5-7-23(20)25)12-11-30(18)10-9-26-24-8-6-21(27(29)32)14-22(24)17-33-26/h2-8,13-14,18,26H,9-12,16-17H2,1H3,(H2,29,32)/t18-,26+/m0/s1

Standard InChI Key:  UXFUUSSXWKKNGT-HFJWLAOPSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 440.55

Molecular Weight (Monoisotopic): 440.2212

AlogP: 3.98

#Rotatable Bonds: 5

Polar Surface Area: 82.59

Molecular Species: BASE

HBA: 5

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 8.65

CX LogP: 3.59

CX LogD: 2.32

Aromatic Rings: 3

Heavy Atoms: 33

QED Weighted: 0.65

Np Likeness Score: -0.90

References

1. Bueno AB, Gilmore J, Boot J, Broadmore R, Cooper J, Findlay J, Hayhurst L, Marcos A, Montero C, Mitchell S, Timms G, Tomlinson R, Wallace L, Walton L..  (2007)  Naphthyl piperazines with dual activity as 5-HT1D antagonists and 5-HT reuptake inhibitors.,  17  (12): [PMID:17434731] [10.1016/j.bmcl.2007.03.101]

Source

Source(1):

• Scientific Literature